Glucocorticoid-induced osteoporosis in dermatologic practice: A review

Yulia K. Khan, Amer N. Kalaaji, Bart Clarke

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Systemic glucocorticoids are widely used in dermatologic practice for various conditions including connective tissue and immunobullous diseases, vasculitis, dermatitis, neutrophilic and other dermatoses, and androgen excess syndromes. Long-term use of systemic glucocorticoids has been associated with substantial and rapid bone loss, which places patients at increased risk for bone fractures. Therefore, bone density measurements and the timely initiation of lifestyle modifications and pharmacotherapy are essential for future bone health. The use of several Food and Drug Administration - approved agents to prevent and treat corticosteroid-induced bone loss has been inconsistent among many specialties. In this review, the authors summarize guidelines on the prevention and treatment of corticosteroid-induced bone loss published by the American College of Rheumatology and supplement these guidelines with descriptions of the latest approved pharmacologic therapies and user-friendly flow algorithms. This summary should aid dermatologists in providing education and recommendations regarding bone health for their patients on systemic glucocorticoids.

Original languageEnglish (US)
Pages (from-to)1053-1059
Number of pages7
JournalJournal of Drugs in Dermatology
Volume7
Issue number11
StatePublished - Nov 2008

Fingerprint

Glucocorticoids
Osteoporosis
Bone and Bones
Adrenal Cortex Hormones
Guidelines
Connective Tissue Diseases
Bone Fractures
Health
Dermatitis
United States Food and Drug Administration
Vasculitis
Skin Diseases
Bone Density
Androgens
Life Style
Education
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Medicine(all)

Cite this

Glucocorticoid-induced osteoporosis in dermatologic practice : A review. / Khan, Yulia K.; Kalaaji, Amer N.; Clarke, Bart.

In: Journal of Drugs in Dermatology, Vol. 7, No. 11, 11.2008, p. 1053-1059.

Research output: Contribution to journalArticle

Khan, Yulia K. ; Kalaaji, Amer N. ; Clarke, Bart. / Glucocorticoid-induced osteoporosis in dermatologic practice : A review. In: Journal of Drugs in Dermatology. 2008 ; Vol. 7, No. 11. pp. 1053-1059.
@article{c1fad102bcab44c0bcbf21d2d01a928b,
title = "Glucocorticoid-induced osteoporosis in dermatologic practice: A review",
abstract = "Systemic glucocorticoids are widely used in dermatologic practice for various conditions including connective tissue and immunobullous diseases, vasculitis, dermatitis, neutrophilic and other dermatoses, and androgen excess syndromes. Long-term use of systemic glucocorticoids has been associated with substantial and rapid bone loss, which places patients at increased risk for bone fractures. Therefore, bone density measurements and the timely initiation of lifestyle modifications and pharmacotherapy are essential for future bone health. The use of several Food and Drug Administration - approved agents to prevent and treat corticosteroid-induced bone loss has been inconsistent among many specialties. In this review, the authors summarize guidelines on the prevention and treatment of corticosteroid-induced bone loss published by the American College of Rheumatology and supplement these guidelines with descriptions of the latest approved pharmacologic therapies and user-friendly flow algorithms. This summary should aid dermatologists in providing education and recommendations regarding bone health for their patients on systemic glucocorticoids.",
author = "Khan, {Yulia K.} and Kalaaji, {Amer N.} and Bart Clarke",
year = "2008",
month = "11",
language = "English (US)",
volume = "7",
pages = "1053--1059",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "11",

}

TY - JOUR

T1 - Glucocorticoid-induced osteoporosis in dermatologic practice

T2 - A review

AU - Khan, Yulia K.

AU - Kalaaji, Amer N.

AU - Clarke, Bart

PY - 2008/11

Y1 - 2008/11

N2 - Systemic glucocorticoids are widely used in dermatologic practice for various conditions including connective tissue and immunobullous diseases, vasculitis, dermatitis, neutrophilic and other dermatoses, and androgen excess syndromes. Long-term use of systemic glucocorticoids has been associated with substantial and rapid bone loss, which places patients at increased risk for bone fractures. Therefore, bone density measurements and the timely initiation of lifestyle modifications and pharmacotherapy are essential for future bone health. The use of several Food and Drug Administration - approved agents to prevent and treat corticosteroid-induced bone loss has been inconsistent among many specialties. In this review, the authors summarize guidelines on the prevention and treatment of corticosteroid-induced bone loss published by the American College of Rheumatology and supplement these guidelines with descriptions of the latest approved pharmacologic therapies and user-friendly flow algorithms. This summary should aid dermatologists in providing education and recommendations regarding bone health for their patients on systemic glucocorticoids.

AB - Systemic glucocorticoids are widely used in dermatologic practice for various conditions including connective tissue and immunobullous diseases, vasculitis, dermatitis, neutrophilic and other dermatoses, and androgen excess syndromes. Long-term use of systemic glucocorticoids has been associated with substantial and rapid bone loss, which places patients at increased risk for bone fractures. Therefore, bone density measurements and the timely initiation of lifestyle modifications and pharmacotherapy are essential for future bone health. The use of several Food and Drug Administration - approved agents to prevent and treat corticosteroid-induced bone loss has been inconsistent among many specialties. In this review, the authors summarize guidelines on the prevention and treatment of corticosteroid-induced bone loss published by the American College of Rheumatology and supplement these guidelines with descriptions of the latest approved pharmacologic therapies and user-friendly flow algorithms. This summary should aid dermatologists in providing education and recommendations regarding bone health for their patients on systemic glucocorticoids.

UR - http://www.scopus.com/inward/record.url?scp=58749117008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58749117008&partnerID=8YFLogxK

M3 - Article

C2 - 19110736

AN - SCOPUS:58749117008

VL - 7

SP - 1053

EP - 1059

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 11

ER -